AUTL
NASDAQAutolus Therapeutics plc
Website
News25/Ratings6
News · 26 weeks64-68%
2025-10-262026-04-19
Mix4190d
- Insider21(51%)
- Other10(24%)
- SEC Filings7(17%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- PRAdvancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial RecognitionAUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of succes
- PRAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company's 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autol
- SECAutolus Therapeutics plc filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form DEL AM filed by Autolus Therapeutics plcDEL AM - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form DEL AM filed by Autolus Therapeutics plcDEL AM - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form S-3 filed by Autolus Therapeutics plcS-3 - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics to Participate in Upcoming Investor ConferencesLONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in two upcoming investor conferences. 25th Annual Needham Virtual Healthcare ConferenceDate and time: April 13, 2028; 10:15am EDT / 3:15pm BSTPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the presentation will be available on the "Events" page in the "Investor Relations & Media" section of the Company's website at https://www.autolus.com/investor-relations-media/events/. A replay of the webca
- SECSEC Form 10-K filed by Autolus Therapeutics plc10-K - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesAUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in pro
- INSIDERSEC Form 3 filed by new insider Richardson Ryan3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Piccina Cintia3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Butitta Cynthia M3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Leiderman Elisabeth3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Will Matthias3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Young William D3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Azelby Robert3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rao Madduri Ravin3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bonney Michael W3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mcilvenny Patrick Paul3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dolski Robert3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bain Linda3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Iannone Robert3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Berriman John E3 - Autolus Therapeutics plc (0001730463) (Issuer)